Scientists decode how cinchona trees build quinine, opening the door to lab-grown production

Overview

Updated May 30

For over two centuries, scientists knew cinchona bark could cure malaria but not how the trees built quinine. Researchers at the Max Planck Institute for Chemical Ecology have mapped every enzymatic step, discovering a previously unknown intermediate and catalytic trick, and published the pathway in Nature on March 18, 2026.

Quinine anchors a roughly two-billion-dollar global market and is a frontline malaria treatment across Central Africa. Its supply depends on plantations in politically fragile regions — chiefly the Democratic Republic of the Congo, producing an estimated 55 percent of global supply. By rebuilding the pathway in engineered organisms, the team showed that quinine can now be produced in laboratory settings, freeing a critical malaria drug from supply risks tied to geopolitics and agriculture.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Timeline Connections

Key Indicators

~$2B

Annual cinchona alkaloid market value

Quinine and related compounds used in malaria treatment, beverages, and industrial chemistry

282M

Malaria cases worldwide in 2024

According to the World Health Organization's 2025 World Malaria Report, with 610,000 deaths

55%

Global quinine supply from the Democratic Republic of the Congo

A single country dominates production, creating significant supply-chain vulnerability

250

Years since scientists began studying cinchona chemistry

The biosynthetic pathway eluded researchers from the late 18th century until this breakthrough

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up

Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Sarah E. O'Connor

Director, Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology

Senior author of the Nature paper

Blaise Kimbadi Lombe

Co-first author, Max Planck Institute for Chemical Ecology

Co-first author of the Nature paper

Tingan Zhou

Co-first author, Max Planck Institute for Chemical Ecology

Co-first author of the Nature paper

Organizations Involved

Max Planck Institute for Chemical Ecology

Research Institute

Published the breakthrough research

A German research institute in Jena focused on the chemical interactions between organisms, including the biosynthesis of plant-derived medicinal compounds.

World Health Organization

International public health agency

Sets global malaria treatment guidelines that include quinine

The United Nations agency responsible for international public health, including setting treatment protocols for malaria that determine how quinine is used worldwide.

Timeline

January 1630 March 2026

9 events Latest: March 19th, 2026 · 5 months ago

Tap a bar to jump to that date

March 2026
Complete quinine biosynthetic pathway published in Nature
Latest Breakthrough

O'Connor's team at the Max Planck Institute publishes the full enzymatic pathway, revealing a novel cinchonium intermediate and a surprising transferase-catalyzed cyclization. They demonstrate that the pathway can be reconstituted in engineered organisms to produce quinine in laboratory settings.
March 19th, 2026
January 2025
Origin of quinine's methoxy group identified
Research

Lombe and colleagues show that quinine's methoxy group traces back to 5-methoxytryptamine as a starting substrate, published in Angewandte Chemie International Edition.
January 1st, 2025
January 2022
Vinblastine pathway reconstituted in yeast
Precedent

Researchers publish the microbial supply chain for the anticancer drug vinblastine in Nature, demonstrating that complex 30-step plant alkaloid pathways can be rebuilt in engineered organisms.
January 1st, 2022
January 2021
O'Connor lab identifies first biosynthetic enzymes
Research

Trenti, Yamamoto, and O'Connor publish the discovery of three enzymes catalyzing early and late steps in quinine biosynthesis, including the dehydrogenase CpDCS and esterase CpDCE.
January 1st, 2021
January 2013
Semi-synthetic artemisinin reaches commercial production
Precedent

Sanofi begins commercial production of the antimalarial artemisinin using engineered yeast — the first successful case of biosynthetic production of a plant-derived antimalarial at industrial scale.
January 1st, 2013
January 2001
First stereoselective total synthesis achieved
Synthesis

Gilbert Stork at Columbia University achieves the first fully stereoselective total synthesis of quinine, settling a decades-long debate about the Woodward-Doering route.
January 1st, 2001
January 1944
First total synthesis of quinine reported
Synthesis

Robert Burns Woodward and William von Eggers Doering report converting quinotoxine to quinine — a formal total synthesis, though not practical for manufacturing.
January 1st, 1944
January 1820
Quinine isolated from cinchona bark
Discovery

French chemists Pierre Joseph Pelletier and Joseph Caventou extract and name the active compound quinine, replacing crude bark with a purified drug.
January 1st, 1820
January 1630
Cinchona bark reaches Europe
Discovery

Spanish Jesuit missionaries bring cinchona bark from Peru to Europe, introducing what will become the world's first effective antimalarial treatment.
January 1st, 1630

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1942–1945

World War II quinine crisis (1942–1945)

When Japan seized the Dutch East Indies in 1942, the Allied powers lost access to roughly 95 percent of the world's quinine supply. Malaria incapacitated more Allied soldiers in the Pacific theater than enemy fire. The crisis spurred emergency programs to develop synthetic alternatives, producing chloroquine and other drugs that would define malaria treatment for decades.

Then

Tens of thousands of Allied troops suffered from malaria due to quinine shortages. Emergency synthetic drug programs produced chloroquine by war's end.

Now

The experience permanently shifted malaria treatment toward synthetic drugs, but also demonstrated the strategic vulnerability of depending on geographically concentrated botanical supply chains — a vulnerability that persists today with Congo-centered production.

Why this matters now

The wartime quinine crisis is the clearest historical demonstration of what happens when a geographically concentrated botanical supply chain breaks. Today's dependence on the Democratic Republic of the Congo echoes the pre-war dependence on the Dutch East Indies, making the biosynthetic alternative strategically as well as economically significant.

2003–2013

Semi-synthetic artemisinin production (2003–2013)

Jay Keasling's lab at the University of California, Berkeley, engineered yeast to produce artemisinic acid — a precursor to the antimalarial artemisinin normally extracted from sweet wormwood plants. The Gates Foundation funded the effort, and Sanofi licensed the technology. By 2013, Sanofi's factory in Garessio, Italy, was producing semi-synthetic artemisinin at commercial scale, reaching 25 grams per liter of artemisinic acid in fermentation.

Then

Semi-synthetic artemisinin provided a price ceiling and supply buffer during periods when plant-derived supply was disrupted by crop failures or speculation.

Now

The project demonstrated that biosynthetic approaches to plant-derived medicines can work at scale, though plant extraction remained dominant when crop yields were high. It became the defining proof-of-concept for synthetic biology in global health.

Why this matters now

The quinine pathway discovery is at the same starting point the artemisinin effort was in the early 2000s — a complete understanding of the biochemistry, with reconstitution in model organisms demonstrated but commercial-scale production still years away. The artemisinin timeline suggests a decade from pathway to factory.

September 2022

Microbial production of vinblastine precursors (2022)

A team spanning multiple universities published in Nature the reconstitution of the 30-plus enzymatic steps needed to produce vinblastine — a critical anticancer drug — in engineered yeast. Vinblastine, like quinine, is a complex plant alkaloid that had resisted biosynthetic production for decades.

Then

The work proved that even extremely long and complex plant biosynthetic pathways could be reconstituted in microbial hosts, though yields remained far below commercial viability.

Now

The vinblastine work expanded the frontier of what synthetic biology could attempt, and the enzymes discovered have been reused in other alkaloid engineering projects.

Why this matters now

Vinblastine and quinine are both complex plant alkaloids in the monoterpene indole alkaloid family. The vinblastine achievement in 2022 demonstrated the feasibility of the same general approach now applied to quinine, and some of the same researchers and techniques were involved in both projects.